Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786383 · ClinicalTrials.gov registry record · Phase 1
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00786383: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT00786383 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00786383, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study. We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.
Interventions
- BIOLOGICAL IMC-1121B
- BIOLOGICAL 1121B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00786383 record still lists
NCT00786383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which IMC-1121B is the first listed.
NCT00786383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00786383 about?
NCT00786383 is a clinical study titled "Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy". We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study. We believe that IMC-1121B blocks the growth factors made by the cancer ce...
What is the current status of trial NCT00786383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00786383?
The interventions under investigation include: IMC-1121B (BIOLOGICAL), 1121B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00786383?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00786383's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia